First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
暂无分享,去创建一个
R. Stahel | R. Rosell | M. Taron | J. Ramírez | M. Sánchez-Ronco | B. Massuti | J. Sánchez | P. Garrido | J. Sánchez | M. Cobo | T. Morán | D. Isla | M. Molina | C. Manegold | J. Trigo | F. Cardenal | P. Lianes | J. Bertran-Alamillo | F. Salazar | B. Massutí